Background: Prostate cancer is the second most common male cancer worldwide, but there is substantial geographical variation suggesting a potential role for modifiable risk factors in prostate carcinogenesis. Methods: We identified previously reported prostate cancer risk factors from the World Cancer Research Fund's (WCRF) systematic appraisal of the global evidence (2018). We assessed whether each identified risk factor was causally associated with risk of overall (79,148 cases and 61,106 controls) or aggressive (15,167 cases and 58,308 controls) prostate cancer using Mendelian randomization (MR) based on genome wide association study (GWAS) summary statistics from the PRACTICAL and GAME-ON/ELLIPSE consortia. We assessed evidence for replication in UK Biobank (7,844 prostate cancer cases and 204,001 controls). Findings: WCRF identified 57 potential risk factors, of which 22 could be instrumented for MR analyses using single nucleotide polymorphisms (SNPs). In MR analyses for overall prostate cancer, we identified evidence compatible with causality for the following risk factors (odds ratio [OR] per standard deviation increase; 95% confidence interval): accelerometer-measured physical-activity, OR=0.49 (0.33-0.72; p=0.0003); serum iron, OR=0.92 (0.86-0.98; p=0.007); body mass index (BMI), OR=0.90 (0.84-0.97; p=0.003); and mono-unsaturated fat, OR=1.11 (1.02-1.20; p=0.02). Findings in our replication analyses in UK Biobank were compatible with our main analyses (albeit with wide confidence intervals). In MR analysis, height was positively associated with aggressive prostate cancer risk: OR=1.07 (1.01-1.15; p=0.03). Interpretation: The results for physical-activity, serum iron, BMI, mono-unsaturated fat and height are compatible with causality for prostate cancer but more research is needed to rule out violations of MR assumptions for some risk factors. The results suggest that interventions aimed at increasing physical activity may reduce prostate cancer risk, but the direction of effects of BMI, and iron are at odds with their effects on other diseases, so the overall public health impact of intervening on these need to be considered.
between circulating mono-unsaturated fat and overall prostate cancer risk.
3 9
None of the risk factors we examined showed strong evidence of association with aggressive prostate cancer 1 4 0 although height showed weak evidence of increasing risk; OR: 1.07; 95% CI: 1.01, 1.15; P=0.03 ( Figure 2 , 1 4 1 Supplementary File 1; Table S4 ).The observational studies also reported positive association of height with 1 4 2 overall prostate cancer (OR: 1.04.; 95% CI: 1.03, 1.05; P=1.3x10 -15 ) and aggressive prostate cancer 8 (OR: 1.04; 1 4 3 95% CI: 1.02, 1.06; P=6.4×10 -5 ). However, our MR analysis did not find evidence of association between height 1 4 4 and overall prostate cancer risk. There was weak evidence for iron, and average acceleration, with effect-1 4 5 estimates being similar to those observed for overall prostate cancers. In the WCRF report, observational studies 1 4 6
have reported positive effects of dairy products, calcium and low selenium concentration on overall prostate 1 4 7
cancer, but we did not find strong evidence of associations with these in our MR analyses ( Figure 1 ). However, 1 4 8 the confidence intervals (CIs) for these risk factors were overlapping between observational and MR analyses.
4 9
The power to detect the observationally reported effect size for these risk factors was >74%). Low alpha-1 5 0 tocopheral concentration was positively associated with prostate cancer risk in WCRF report but due to lack of 1 5 1 an instrument it was not possible to conduct MR analyses.
5 2
There were only two SNPs available for the MR analysis of physical-activity (average acceleration) so we could 1 5 3 not perform extensive sensitivity analyses. The direction of association for both SNPs was consistent 1 5 4 (Supplementary File 1; Table S5 ) and the p-value for heterogeneity test was 0.99. These SNPs were on different 1 5 5 chromosomes so represent independent associations. After exploring MRBASE-PheWAS Replication 1 7 2
The MR analyses were repeated using prostate cancer summary data generated from UK Biobank for physical-1 7 3 activity, iron, BMI, and mono-unsaturated fat (Figure 3) . The point-estimates showed consistent directions of 1 7 4 association for physical-activity (OR: 0.37; 95% CI: 0.13, 1.06; P=0.07), and BMI (OR: 0.83, 95% CI: 0.74, 1 7 5 0.94; P=0.002). The point-estimates for iron (OR: 1.07; 95% CI: 0.96, 1.20; P=0.24) and mono-unsaturated fat 1 7 6 (OR: 0.89; 95% CI: 0.73, 1.07; P=0.20) were in the opposite direction, but the power to detect an effect with 1 7 7 these risk factors in UK Biobank was low and confidence intervals for the replication analysis overlapped with 1 7 8
our main analysis for all risk factors.
1 7 9 1 8 0 Discussion 1 8 1
We found consistent evidence that physical-activity (assessed as 'average accelerations', but not other measures 1 8 2 of physical activity), and BMI have an inverse effect on overall prostate cancer risk. There was also evidence of 1 8 3 an inverse effect of iron and a positive effect of circulating mono-unsaturated fat in our initial analyses, the 1 8 4 effect sizes were in opposite direction in UK Biobank study however power for the replication analysis was low 1 8 5
and their CIs overlapped with the PRACTICAL study. There was weak evidence for physical-activity (average 1 8 6 accelerations), and iron had a similar effect on aggressive prostate cancer to that seen for overall prostate cancer.
8 7
We found little evidence that any of the other risk factors studied have a causal role in overall or aggressive 1 8 8 prostate cancer, but height showed a positive association with aggressive prostate cancer. The CIs of MR results 1 8 9 overlapped with those seen in the observational analyses for all risk factors except for average acceleration and 1 9 0 mono-unsaturated fat (overall prostate cancer). In fact, confidence intervals for our MR analysis of aggressive 1 9 1 prostate cancer were wide and the power for these analyses was low for many risk factors.
9 2
The WCRF report meta-analysed self-reported physical-activity which was assessed in different studies by 1 9 3 various methods (i.e. occupational, recreational and total physical-activity) as highest versus lowest level of total 1 9 4 physical-activity, a relatively crude dichotomy that may have masked associations. Our MR analysis which 1 9 5 proxied fraction accelerations was the most similar to the observational analyses and we did not find evidence of 1 9 6 an association of this measure with prostate cancer. However, we did find an association with average 1 9 7 acceleration, which is a different measure and could be high if someone is consistently engaging in light-1 9 8 intensity activity across most of the waking day (vs lots of sitting and a 30 minutes bout of MVPA). Indeed, 1 9 9 there is little genetic or phenotypic correlation between the two measures in the UKBiobank population 29 . The 2 0 0 mechanism for our association between average accelerations and prostate cancer is unclear, although this could 2 0 1 be through improved insulin sensitivity or reduced insulin-like growth factor-1 (IGF-1) 30 , reduced levels of 2 0 2 testosterone and dihydrotestosterone 31 , alterations in the antioxidant defence system 31 , or improvements in the 2 0 3 immune system through enhanced natural killer cell activity 31 .
0 4
Whilst not consistent with observational analyses, our results for BMI are concordant with other lines of 2 0 5 evidence. We have previously shown weak evidence that higher BMI is associated with a reduced prostate 2 0 6 cancer risk, in a smaller sample from the PRACTICAL consortium 32 . A study examined childhood and adult 2 0 7 body size in relation to total incident prostate cancer in a prospective cohort of 47,491 US men 33 . High BMI at 2 0 8 age 21 was inversely associated with total prostate cancer, with fatal and advanced disease. The association for 2 0 9 late adult BMI was more complex and differed by age this could represent confounding by other factors for 2 1 0 example physical activity, and diet etc.
1 1
Despite showing a protective effect of BMI on prostate cancer risk, we did not find any strong evidence of waist 2 1 2 circumference or WHR with risk. However, the results for all these risk factors were in the same direction. The 2 1 3 point estimates for BMI, waist circumference and WHR were in the opposite direction to findings from 2 1 4 observational results for aggressive prostate cancer. For aggressive prostate cancer, power calculations 2 1 5 suggested that we would have good power to detect an effect of BMI (96%) but very low power (33% and 23%) 2 1 6 to detect an OR of 1.20 (or, conversely a protective OR of at least 0.80) for waist circumference and WHR 2 1 7
respectively. An increased estrogen production has been observed in obese men 34 . The sensitivity of prostate 2 1 8 cancer to sex hormones has been exploited for therapeutic purposes for many years. Androgen-deprivation 2 1 9 therapy is a common treatment in prostate cancer 35 , as is the therapeutic use of estrogen for patients with 2 2 0 metastatic prostate cancer in both the US 36 and Europe 37 , though not popular due to cardiovascular and other 2 2 1 side effects. Hence the clinical prediction would be that obesity would be associated with a lower risk of 2 2 2 prostate cancer. However, we cannot rule out detection bias 38 arising from delayed diagnosis and therefore a 2 2 3 more advanced stage at diagnosis in obese men. This could arise due to lower accuracy of digital rectal 2 2 4 examination in obese men or lower PSA values caused by obesity-related traits.
5
The analysis of iron as a risk factor for prostate cancer found that the evidence was too limited to draw 2 2 6 conclusions in the WCRF Second Expert Report and this was not updated in the Third Expert Report due to a 2 2 7 lack of new evidence 8, 39 . Population studies that have examined the associations between serum iron and cancer 2 2 8 outcomes are limited and have reported discordant findings. A prospective cohort study with 15-16 years follow 2 2 9 up time reported higher serum iron concentrations increased non-skin cancer risk overall but conversely, in men, 2 3 0 higher serum iron concentrations decreased the risk of non-skin cancer 40 . A Swedish cohort reported increased 2 3 1 serum iron concentrations were not associated with overall cancer risk except for a slightly higher risk of 2 3 2 postmenopausal breast cancer 41 . Previous findings have suggested that, although higher circulating iron 2 3 3 concentrations may potentially increase the risk of cancer in women it may be protective against cancer in men 40 2 3 4 which is in accordance with our MR findings. Although again we were unable to replicate these findings in UK 2 3 5 Biobank due to low power.
3 6
Our MR-analysis investigated the association of circulating levels of mono-unsaturated fat on prostate cancer, 2 3 7 circulating levels of this nutrient have been shown to be poorly correlated with mono-unsaturated fat intake 2 3 8 measured by questionnaire 42 . The inclusion of an objective measure in our MR-analysis versus questionnaire 2 3 9 data in observational studies could be the reason for the discordant results. Although discordance could also be 2 4 0 due to negative confounding in the former studies resulting in the effect estimate being closer to the null (e.g., 
4 5
Our MR results showed positive association between height and aggressive prostate cancer and the results was 2 4 6 consistent with observational studies. Adult height is associated with the rate of growth during fetal life and 2 4 7 childhood 43,44 .Health and nutrition status in the neonatal period and childhood may affect the age of sexual 2 4 8 maturity. These processes are mediated by changes in the hormonal microenvironment that may have both short 2 4 9 and long term effects on circulating levels of growth factors, insulin and other endocrine or tissue specific 2 5 0 mediators that may impact cancer risk 45 .
5 1
The results from replication analyses were compatible with the main findings for BMI, and physical activity 2 5 2 (albeit with wide confidence intervals for physical activity), which increases the likelihood that these findings 2 5 3 are real. The UK Biobank sample size was however, smaller, and the effects were estimated with less precision 2 5 4 and whilst the results for iron and mono-unsaturated fats did not appear to replicate, due to low power in the 2 5 5 replication study we cannot rule out causal effects of these nutrients.
5 6
This study's major strength is the use of MR, which is less susceptible to problems of measurement error, 2 5 7 confounding and reverse causation in comparison to conventional observational studies. The use of two-sample 2 5 8 MR enabled the use of the largest GWAS of prostate cancer 21 to date. We were also able to make use of the 2 5 9 largest GWASs on the risk factors of interest, to increase the precision of the SNP-exposure estimates, which 2 6 0 should reduce impact of weak instruments bias, which in turn increase statistical power assuming the SNP-2 6 1 exposure estimates are unbiased and risk factor/outcome samples come from the same population.
6 2
The study also has some limitations. We had only two SNPs for physical-activity assessed as average 2 6 3 acceleration. If there were many independent SNPs available the causal inference could have been strengthened 2 6 4 because a) each variant represents an independent natural experiment, and a more precise overall causal estimate 2 6 5 (i.e. tighter CIs) can be obtained by meta-analysing the single estimates from each instrument; and b)potential 2 6 6 bias arising from the violation of the assumptions can be detected or corrected by evaluating the consistency of 2 6 7 effects across instruments 16, 24, 28, 46, 47 . For many of the risk factors reported in the WCRF 2018 report, for 2 6 8 example alpha-tocopheral, vitamin A, vitamin C etc, we did not find genetic instruments to conduct MR 2 6 9 analyses. For the majority of the risk factors in overall prostate cancer, MR analyses were sufficiently powered 2 7 0 to detect effect sizes of a modest magnitude (OR of 1.20 or 0.80) except for physical-activity traits (overall 2 7 1 acceleration average, fraction of accelerations >425 milli-gravities, and sedentary behaviour), thus failure to 2 7 2 detect strong evidence of effects for these risk factors could be due to low power to detect smaller effect sizes.
7 3
Further identification of independent genetic variants that influence these risk factors will help to improve 2 7 4 statistical power for future analyses.
7 5
In conclusion, we found evidence that physical-activity, serum iron, and BMI may be causally and inversely 2 7 6 related to and circulating mono-unsaturated fat and height may be causally and positively related to, prostate 2 7 7 cancer risk. Further studies should investigate the mechanisms by which these factors may lead to prostate 2 7 8 cancer and investigate the potential to intervene to reduce risk. Only those risk factors are plotted whose observational estimates were reported in WCRF Second or Third 
